Profound Medical Corp. 01.23.17
Profound Medical Corp., an emerging medical device company focused on prostate care, has appointed Kenneth Galbraith to its Board of Directors. In connection with Galbraith’s appointment, Steven Plymale has resigned from the company’s board, but remains president and chief operating officer.
Galbraith is an accomplished life sciences industry veteran with more than 25 years of experience acting as an executive, director, investor and advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors. Galbraith joined Ventures West as a general partner in 2007 and led the firm’s biotechnology practice prior to founding Five Corners Capital in 2013 to continue management of the Ventures West investment portfolio. Previously, he served as the chairman and interim CEO of AnorMED until its sale to Genzyme Corp. in a cash transaction worth almost $600 million.
“I am very pleased to welcome Ken to the Board of Directors,” said Damian Lamb, board chairman. “Ken has a strong track record of helping emerging life sciences companies develop into industry leaders, and I am confident that his expertise and guidance will be of significant benefit to Profound and its shareholders.”
Starting his career in the life sciences sector in 1987, Galbraith spent 13 years in senior management with QLT Inc., retiring in 2000 from his position as executive vice president and chief financial officer when QLT’s market capitalization exceeded $5 billion. He has served on the Board of Directors of several public and private companies, including Angiotech Pharmaceuticals, Arbutus Biopharma, and Cardiome Pharma. Galbraith currently serves on the Board of Directors of Macrogenics and Prometic Life Sciences. Galbraith earned an honors degree from the University of British Columbia (BC) in 1985 and was appointed a fellow of the Chartered Accountants of BC in 2013.
“This is an exciting time for Profound as it embarks on a period of anticipated rapid global growth. I am looking forward to working with Profound’s leadership team to help the company realize its potential to become a leader in prostate cancer care,” said Galbraith.
Profound Medical team is working to achieve a new therapeutic standard in prostate cancer. Established in 2008, the company is commercializing a technology, TULSA-PRO, which combines real-time magnetic resonance imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control that is designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects. TULSA-PRO is CE Marked and Profound is sponsoring a multicenter, prospective U.S. Food and Drug Administration-registered clinical trial, TACT, which is designed to further demonstrate the safety and effectiveness of the technology.
Galbraith is an accomplished life sciences industry veteran with more than 25 years of experience acting as an executive, director, investor and advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors. Galbraith joined Ventures West as a general partner in 2007 and led the firm’s biotechnology practice prior to founding Five Corners Capital in 2013 to continue management of the Ventures West investment portfolio. Previously, he served as the chairman and interim CEO of AnorMED until its sale to Genzyme Corp. in a cash transaction worth almost $600 million.
“I am very pleased to welcome Ken to the Board of Directors,” said Damian Lamb, board chairman. “Ken has a strong track record of helping emerging life sciences companies develop into industry leaders, and I am confident that his expertise and guidance will be of significant benefit to Profound and its shareholders.”
Starting his career in the life sciences sector in 1987, Galbraith spent 13 years in senior management with QLT Inc., retiring in 2000 from his position as executive vice president and chief financial officer when QLT’s market capitalization exceeded $5 billion. He has served on the Board of Directors of several public and private companies, including Angiotech Pharmaceuticals, Arbutus Biopharma, and Cardiome Pharma. Galbraith currently serves on the Board of Directors of Macrogenics and Prometic Life Sciences. Galbraith earned an honors degree from the University of British Columbia (BC) in 1985 and was appointed a fellow of the Chartered Accountants of BC in 2013.
“This is an exciting time for Profound as it embarks on a period of anticipated rapid global growth. I am looking forward to working with Profound’s leadership team to help the company realize its potential to become a leader in prostate cancer care,” said Galbraith.
Profound Medical team is working to achieve a new therapeutic standard in prostate cancer. Established in 2008, the company is commercializing a technology, TULSA-PRO, which combines real-time magnetic resonance imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control that is designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects. TULSA-PRO is CE Marked and Profound is sponsoring a multicenter, prospective U.S. Food and Drug Administration-registered clinical trial, TACT, which is designed to further demonstrate the safety and effectiveness of the technology.